1. High takeover premiums – Biotech takeovers typically feature significant control premiums. Since 2020, the average biotech takeover premium was 87.5%, compared to the M&A universe average (ex-biotech) of 41.7%. In addition, takeover over premiums in the biotech sector can soar to truly astronomical levels, with seven deals featuring a takeover premium above 200%, two north of 300%, and one at a stunning 667% premium. Large takeover premiums are extremely rewarding to investors.
As PAA has a First in Class Medicine with multiple known targets and Clinical data in Oncology and Covid , HVTL-1 etc we should be asking a swerious premium , plus our Tablet cost is low , $1.50 to $2.00 a Tablet ,, Huge margins here NZT
1. High takeover premiums – Biotech takeovers typically feature...
-
- There are more pages in this discussion • 37 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
17.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $85.12M | |||
| Open | High | Low | Value | Volume |
| 18.0¢ | 18.0¢ | 17.0¢ | $141.2K | 801.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 11 | 537419 | 17.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 18.0¢ | 140000 | 3 |
View Market Depth
| Last trade - 16.10pm 06/09/2024 (20 minute delay) ? |
| PAA (ASX) Chart |